Find drugs by alphabetical list:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z View All
Zavesca treatment discontinued for Niemann-Pick Type C child - Examiner.com
Zavesca treatment discontinued for Niemann-Pick Type C childExaminer.comTabitha Wheeler, the West Columbia SC child who struggles with a rare genetic disease called Niemann-Pick Type C, has been taken off the drug Zavesca ...
Actelion Pharmaceuticals Ltd: Actelion announces third quarter 2010 financial ... - Reuters (press release)
Actelion Pharmaceuticals Ltd: Actelion announces third quarter 2010 financial ...Reuters (press release)Sales of Zavesca (miglustat) for the third quarter of 2010 increased by 11 percent in local currencies to reach CHF 16.2 million compared to CHF 15.9 ...and more��
Actelion reports sales growth in third quarter - Zenopa
Actelion reports sales growth in third quarterZenopaProducts which saw improved sales during the quarter included Tracleer and Zavesca, with increasing patient demand cited as the reason behind the trend. ...
Actelion Beats, Confirms Outlook - Zacks.com
Actelion Beats, Confirms OutlookZacks.com... and Zavesca, whose sales increased 11% year over year during the third quarter, given recent approvals in Australia, New Zealand, Columbia and Turkey. ...and more��
Last updated on: Jan 24, 2007
Brand Name: | Zavesca |
Active Ingredient: | miglustat |
Strength(s): | 100 mg |
Dosage Form(s): | Capsule |
Company Name: | Galen Limited; Actelion Pharmaceuticals US Inc. |
Availability: | Prescription only |
*Dated Approved by FDA: | July 31, 2003 |
*Approval by FDA does not mean that the drug is available for consumers at this time.
This information is provided by the U.S. Food & Drug Administration.
For more information about this drug, click here. |
Zavesca is used to treat adults with mild to moderate type I Gaucher disease. Zavesca is only used in patients who cannot be treated with enzyme replacement therapy. Zavesca has not been studied in children under 18 years of age.
Type I Gaucher disease is an inherited disease that you get from both your parents. People with Type I Gaucher disease are missing an enzyme that breaks down a chemical in the body called glucosylceramide. Too much glucosylceramide causes liver and spleen enlargement, changes in the blood, and bone disease. Zavesca may stop glucosylceramide from forming.
Who should not take Zavesca?
Do not take Zavesca if you are allergic to any of its ingredients. The active ingredient is miglustat.
Special Warnings with Zavesca:
Do not get pregnant while taking Zavesca. Men and women should use effective birth control during treatment with Zavesca. Men should keep using effective birth control for 3 months after treatment with Zavesca stops.
General Precautions with Zavesca:
What should I tell my doctor or health care provider?
Tell your doctor before taking Zavesca:
What are some possible side effects of Zavesca? (This is NOT a complete list of side effects reported with Zavesca. Your health care provider can discuss with you a more complete list of side effects.)
Diarrhea is the most common side effect for people taking Zavesca. You may also lose weight when you start treatment with Zavesca. Some of the other side effects of Zavesca include:
Accupril
Actonel
Actos
Allegra
Altace
Atenolol
Avandia
Celebrex
Celexa
Cialis
Coreg
Cozaar
Crestor
Diovan
Effexor
Evista
Flomax
Fluoxetine
Fosamax
Glucophage
Latisse
Levitra
Levoxyl
Lexapro
Lipitor
Lisinopril
Metformin
Neurontin
Nexium
Norvasc
Paxil
Plavix
Pravachol
Premarin
Prevacid
Prilosec
Propecia
Protonix
Prozac
Seroquel
Simvastatin
Singulair
Toprol-XL
Viagra
Zetia
Zithromax
Zocor
Zoloft
Zyprexa
Zyrtec